Abstract: Iron-overloaded b-thalassaemia major (BTM) children have high risk of delayed sexual/physical maturation, liver/heart diseases and reduced life expectancy. The lifelong need to use iron chelators, their unpleasant administration, side effects and lack of awareness regarding iron overload risks all hamper BTM patient compliance to iron chelators. This study evaluated the impact of clinical pharmacist-provided services on the outcome of iron-overloaded BTM children. Forty-eight BTM children were randomly assigned to either control group, who received standard medical care, or intervention group, who received standard medical care plus clinical pharmacist-provided services. Services included detection of drug-related problems (DRPs) and their management, patient education regarding disease nature and iron chelators, as well as providing patient-tailored medication charts. After six months of study implementation, there was a highly significant difference between the control and intervention groups in serum ferritin (SF) (mean: 3871 versus 2362, lg/l, p = 0.0042), patient healthcare satisfaction (median: 24.47 versus 90.29, p < 0.0001) and quality of life (QoL) (median: 49.84 versus 63.51, p = 0.0049). The intervention group showed a decline from baseline to the end of study in DRPs (64-4), the number of non-compliant patients (24-3) and mean SF levels (3949-2362 lg/l, p < 0.0001). Clinical pharmacist-provided services can positively impact the outcome of BTM children.
Thalassaemia is one of the most common genetic disorders with a high occurrence in the 'thalassaemia belt' extending from the Mediterranean basin through the Middle East to South-East Asia [1] . Most of paediatric patients with thalassaemia are born in low-income countries where it was reported that 50,000-100,000 children with beta-thalassaemia major (BTM) die each year in low-and middle-income countries [2, 3] . Beta-thalassaemia is considered to be the most frequent haemoglobinopathy in Egypt with a carrier rate ranging from 5.3 to ≥9% and a gene frequency of 0.03. Every year, the estimated number of live births born with beta-thalassaemia is 1000/1.5 million [4] .
Iron overload is one of the major complications in patients with BTM arising from obligatory lifelong transfusions of packed red blood cells, ineffective erythropoiesis and increased gastrointestinal iron absorption [5, 6] . Iron overload places the patient at high risk of delayed sexual and physical maturation, liver and heart diseases and reduced life expectancy [7, 8] . Although iron chelation therapy is considered the rescue medication for these patients, it is misperceived by most of the patients. Many iron chelation therapy (ICT)-related issues act as obstacles to its successful use including the lifelong need to its use, unpleasant administration, high side effect profile and lack of patient awareness regarding iron overload risks [9] .
Clinical pharmacy services aim to provide comprehensive medication management that optimizes patient outcome [10] . Many studies have emphasized the positive impact of clinical pharmacy services on the detection of drug-related problems (DRPs) and patient outcome in various clinical settings [11] [12] [13] [14] . DRPs include all the issues that may interfere with the success of pharmacotherapy, and are closely linked to reduced clinical benefits of treatment and poor patient outcome [15] . It was previously suggested that inadequate pharmacy services may be one of the risk factors contributing to the occurrence of DRPs [16] . Till today, no studies have assessed the occurrence of DRPs in paediatric BTM patients. To the best of our knowledge, this is the first study to evaluate the occurrence of DRPs in iron-overloaded paediatric BTM patients and to investigate the impact of providing clinical pharmacy services to these patients.
Methods
The study protocol was revised and approved by the research ethics committee for experimental and clinical studies at the Faculty of Pharmacy, Ain Shams University, Cairo, Egypt, on 10 September 2014. The study was performed in accordance with the Declaration of Helsinki. The study was a prospective, randomized, controlled study. It was conducted on paediatric BTM patients admitted to the Pediatric Hematology Clinic, Children's Hospital, Ain Shams University, from November 2014 to July 2015 with a six-month period of follow-up. than 1000 lg/l, while the exclusion criterion was only patients with cognitive impairment. At enrolment, 56 patients were assessed for eligibility, where eight patients were excluded (six with SF > 1000 lg/l and two with age ≤ 8 years). Stratified randomization was used considering the iron chelation therapy as the stratification factor, where 48 patients were allocated to either the control group or the intervention group. The control group (n = 24) received standard medical care by a physician, while the intervention group received standard medical care plus clinical pharmacist-provided services. During the six-month period of the study, all patients were assessed every 3 months for SF levels, serum creatinine (SCr) and alanine transaminase (ALT) levels. Also, patients' quality of life (QoL) and healthcare satisfaction were assessed at baseline and after 6 months of the study using PedsQL TM 1 Assessment: The clinical pharmacist gathered and recorded patient demographics, medication profiles including both prescription and non-prescription medications and laboratory data including SF, ALT and SCr levels from all the patients at baseline. 2 DRP identification: The clinical pharmacist analysed the collected data to detect whether any DRPs existed and allocated them to one of the seven categories as classified by Cipolle et al. [18] : unnecessary drug therapy, need for additional drug therapy, ineffective drug product, dosage too low, adverse drug reaction (ADR), dosage too high, non-compliance. 3 Care plan development: Care plan development included interventions to resolve drug therapy problems, achieve goals of therapy and prevent drug therapy problems. Mainly three interventions were performed, namely Dosage regimen modification: Based on the iron overload status reflected by SF levels, any needed dosing regimen modification was recommended and performed.
Patient education:
The clinical pharmacist created a simplified tailored educational material in the form of a story with various episodes for patient education (Data S1). At every visit, the patients and their caregivers were educated on disease nature, complications, risks of iron overload and how to control it, types of iron chelators, maximizing benefit from iron chelation regimen, impact of adherence to treatment and finally their dietary requirements.
Patient compliance follow-up: Regular phone calls and a patient-tailored medication chart detailed with drug dose, frequency and administration precautions were used ( fig. S1 ).
4 Patients' follow-up evaluation: Patients in both groups were subjected to the following:
SF levels were measured at baseline, 3 months and after 6 months. CBC with WBC differential was assessed at every visit, and SCr and ALT were measured routinely for all the patients every three months.
Health-related quality of life (HRQoL) was assessed at baseline and at the end of the study (after 6 months) using PedsQL TM 4.0 Generic Core Scale Questionnaire. PedsQL is a 23-item multi-dimensional model with four domains for paediatric HRQoL measurement: physical functioning (eight items), emotional functioning (five items), social functioning (five items), and school functioning (five items) [19] . Healthcare satisfaction was assessed at baseline and at the end of the study (after 6 months) using PedsQL TM Healthcare Satisfaction Hematology/Oncology Module, which is a 24-item questionnaire consisting of six domains associated with healthcare satisfaction: information (five items), family inclusion (four items), communication (five items), technical skills (three items), emotional needs (four items) and overall satisfaction (three items) [20] . This questionnaire evaluates parent satisfaction with the health care for their children [21] .
Statistical analysis. Statistical analysis was performed using GraphPad 6 (GraphPad Software, Inc., La Jolla, CA, USA). Paired t-test and Wilcoxon's signed rank test were used for within-group comparisons, while between-group comparisons were made using the unpaired t-test and the Mann-Whitney U-test. The overtime change was compared using repeated-measures one-way ANOVA with Bonferroni's post hoc pairwise comparison. Fisher's exact and chi-squared tests were used to compare categorical data. A cut-off for p-value <0.05 was considered to be significant.
Results

Baseline evaluation.
At baseline, there was no significant difference between the two groups in terms of patient demographics, clinical characteristics, laboratory parameters or PedsQL TM total scores (table 1). A total of 64 DRPs were detected at baseline in the intervention group where patient non-adherence was the major DRP in this group ( fig. 1 ).
End of study evaluation.
Drug-related problems. After 6 months of clinical pharmacist intervention, DRPs declined from a total of 67-4. Table 2 illustrates the change in various types of DRPs over the study period and the percentage of acceptance and implementation of these interventions.
Serum ferritin. After 6 months of clinical pharmacist intervention, the intervention group showed a highly significant decrease in the mean SF levels compared to the control group (p = 0.0042). Also, the intervention group showed a highly significant decrease in the percentage change in the SF levels compared to the control group (p < 0.0001) (table 3, fig. 2 ).
Using one-way repeated-measures ANOVA, the change over time from baseline to 3-6 months revealed a highly significant decline in the intervention group's mean SF levels (p < 0.0001) versus the control group that showed no significant change (p = 0.4140) ( fig. 3 ).
Healthcare satisfaction and HRQoL. The intervention group showed a highly significant increase in the PedsQL TM total score of both the HRQoL and healthcare satisfaction questionnaires (p = 0.0049, p > 0.0001, respectively) compared to the control group (table 3, figs 4 and 5).
There was a significant moderate negative correlation between PedsQL TM healthcare satisfaction scores and SF levels (rs = À0.4204, p < 0.0001), while no statistically significant correlation was found between PedsQL TM HRQoL total scores and SF levels (rs = À0.0296, p = 0.7745).
Discussion
The current study showed that after 6 months of providing clinical pharmacy services to iron-overloaded paediatric BTM patient, there was a significant improvement in DRPs, patient compliance to iron chelators, SF levels, patient healthcare satisfaction and HRQoL in the intervention group versus control. The current study reported several DRPs, with the highest occurrence for non-adherence to iron chelation therapy (ICT), which was as well reported in other studies. Porter et al. explained that patient non-adherence to ICT is a common and major problem in patients with BTM and is directly reflected on their iron overload status and consequently on their survival [22] . Several other studies have shown that patients who comply with ICT, and whose iron levels are therefore well controlled, have better survival rates than those who are noncompliant [23] [24] [25] [26] .
A cross-sectional study of 32 patients with BTM revealed that most of the patients had inadequate knowledge about their disease and its treatment. The authors reflected this to the lack 
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of explanation from healthcare providers and patients' fear of receiving disease-related information. They recommended improving the quality of patient care and providing practical knowledge about the disease to patients to improve patient adherence to treatment [27] .
The present study tackled the DRP of patient non-compliance via patient education using a tailored educational material in the form of a story. The parents of patients were also enrolled in the educational sessions. This enhanced the opportunity for good communication between the clinical pharmacist, the children and their parents. Also, medication charts were perceived by many children as competitive assignments to achieve, which encouraged them to stick more to their medication.
After 6 months of the current study implementations, the number of non-compliant patients in the intervention group decreased from 100% to 12.5% of the group. This finding aligns with the conclusion of Pakbaz et al. [28] that patient education and iron overload status monitoring may help in improving patient compliance to ICT.
In the current study, ADR was the second most common DRP reported at baseline in the intervention group. Cipolle et al. [29] have previously classified ADR into several categories, yet in the current study only three were reported, namely incorrect administration, drug interaction and undesirable effect. Educating the patients about the proper administration of medications helped decrease DRP to a high degree (100%) of patient acceptance for pharmacist interventions.
The inappropriate dose of ICT -either too low or too high -was reported in 66.6% of patients in the intervention group at baseline. This was attributed to the infrequent monitoring of SF levels in many patients due to patients' financial constraints and lack of health insurance coverage. Hence, most of the previously calculated ICT doses were based on outdated patient SF levels and also that physician-initiated dose modifications were not followed up and the patients used to skip the prescribed doses. Throughout the 6-month period of the study, SF levels were regularly assessed (every three months) for all the patients and recorded in patients' files, and doses were modified accordingly.
Another evaluated DRP was the ineffective drug use that was reported in four patients who skipped their doses of ICT due to inconvenient dosage form of oral syrup with poor palatability. The pharmacist recommended shifting the patients to oral tablets.
Several studies have previously reported elevated SF levels in patients with BTM that were linked to increased blood transfusion frequency and lack of patient adherence to ICT therapy [30] [31] [32] . Similarly, in the current study, the baseline SF levels were elevated in the control and intervention group (mean: 3871 lg/l versus 3949 lg/l, respectively).
After 6 months of study implementation, the intervention group showed a highly significant decrease in the mean SF levels from baseline as compared to the control group and a highly significant decrease in the percentage change in the mean SF levels compared to the control group (À35.89% versus À1.648%, p < 0.0001). Hence, when looking at the highly significant improvement in the SF levels in the intervention group by the end of the study, either compared to its baseline or to the control group, it can be interpreted as being the direct reflection of enhanced patient compliance to ICT.
A significant improvement in the Pediatric Quality of Life Inventory (PedsQL TM 4.0) total score was reported in the intervention group by the end of the study. This could be attributed to the decline in DRPs in the intervention group that contributed to better compliance and patient satisfaction with therapy. Various studies have linked the negative impact of the disease on the patients' HRQoL to different factors such as the presence of disease complications and patients' educational level [33, 34] .
Two studies reported no significant relationship of SF level to HRQoL among children with thalassaemia [19, 35] . This finding supports our results that found no statistically significant correlation between total PedsQL TM scores and SF levels. This can be explained by the fact that the deleterious effects of iron overload are not evident on the short-term follow-up and most of the complications can be much pronounced in the long-term of the patients' life.
On the other hand, a highly significant improvement in patient healthcare satisfaction was reported in the intervention group by the end of the study. These findings could be attributed to the provision of clinical pharmacy services to these patients, which enhanced the perceived care by the children and their parents. Similarly, it was previously reported that in paediatric patients with chronic disease, there is a positive correlation between good physician-children communication and patient satisfaction and adherence [36] . This aligns with our finding of positive correlation between PedsQL TM healthcare satisfaction total scores and SF levels. Hence, enhanced patient satisfaction encouraged prompt adherence to ICT, which was directly reflected on their SF levels.
In conclusion, this is the first study to address DRPs in paediatric patients with BTM where various DRPs were reported and patient non-adherence to ICT represented the major DRP arising in these patients. Providing clinical pharmacy services to paediatric patients with BTM improved patients' compliance, SF levels, quality of life and healthcare satisfaction. Enrolment of a clinical pharmacist as an integral member of the healthcare team of children with BTM can positively impact the clinical outcome of children with BTM.
